NEWS
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference "RNA at the Bench and Bedside IV"
Wednesday, 11th December at 6:30 pm
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing
MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes
Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells
Wednesday, 11th December at 6:30 pm
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing
MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes
Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells
EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a talk titled "Specific and efficient genome editing with metagenomics-derived tools for in vivo and ex vivo therapeutic applications" at the Nature Conference: RNA at the Bench and Bedside IV.
"We believe the value proposition for single-dose gene editing therapies requires exquisite specificity characterization to ensure safety and efficacy. Today's presentation highlights the precision of Metagenomi's next-generation nucleases and ABEs, discovered through the company's proprietary metagenomics platform and tailored for both in vivo and ex vivo therapeutic applications," said Alan Brooks, SVP and Head of Preclinical. "MGX-001, Metagenomi's development candidate for hemophilia A, which utilizes the novel nuclease MG29-1, exhibits no identifiable off-target editing using a series of orthogonal assays employed to evaluate potential off-target sites in the genome.
The MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes. For Metagenomi's novel next-generation ABE for ex vivo cell therapy indications via multiplex editing, the data showed no detectable translocations and no significant genomic base composition differences in primary T-cells when compared to unedited cells. These examples demonstrate our strong capabilities in developing highly specific next-generation gene editing tools and support the company's ability to potentially progress these systems toward the clinic for the benefit of patients."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
3681Followers
73Following
40KVisitors
Follow
Lnova : Thank you for sharing this. I didn’t know about this company. I am fascinated by genetics, genealogy, and especially DNA. I am very interested in following stocks that work in this area. I think it is something that is very relevant, and will only become more relevant and having more uses for going forward into the future.